Octapharma announced today the results from the ProDERM study on the efficacy and safety of Octagam® 10% [Immune Globulin Intravenous (Human)], in adult dermatomyositis (DM) patients have been published in…
Continue Reading
Kezar Announces Topline Results from PRESIDIO Trial of Zetomipzomib for the….
Today, Kezar Life Sciences announced topline results from the PRESIDIO study, evaluating the efficacy and safety of zetomipzomib in dermatomyositis and polymyositis. In this study, most patients experienced a clinically…
Continue Reading
TMA’s Women with IBM Affinity Group – Kelly Beer (IBM Research and Drug Trials)
Clinical Research Manager, Myositis Discovery Programme Centre for Molecular Medicine and Innovative Therapeutics (CMMIT) Murdoch University, Perth, Australia Her program and discussion will include: Upcoming Research Opportunities Current Active Research…
Continue Reading
FDA Approves Octapharma’s Octagam® 10% for Adult Dermatomyositis
The U.S. Food and Drug Administration (FDA) has granted approval to Octapharma USA for Octagam® 10% the first and only intravenous immunoglobulin (IVIg) to be indicated for the treatment of…
Continue Reading
COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic and Musculoskeletal Diseases
Developed by the ACR COVID-19 Vaccine Clinical Guidance Task Force. Click here to view information.
Continue Reading